Core–Shell Nanoparticles with Sequential Drug Release Depleting Cholesterol for Reverse Tumor Multidrug Resistance
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.4c17858 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Jieke Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Doxorubicin, Nanoparticles, Drug Resistance, Neoplasm, Cholesterol. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou 450001, Henan, China.
ORCID-Profile: Bin Du
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J., Zhou, Y., Guo, J., Yan, M., Liu, C., & Du, B. (2025). Core–Shell Nanoparticles with Sequential Drug Release Depleting Cholesterol for Reverse Tumor Multidrug Resistance. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c17858
Vancouver
Zhang J, Zhou Y, Guo J, Yan M, Liu C, Du B. Core–Shell Nanoparticles with Sequential Drug Release Depleting Cholesterol for Reverse Tumor Multidrug Resistance. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c17858
BibTeX
@article{Zhang2025,
author = {Zhang, Jieke and Zhou, Yingying and Guo, Jialing and Yan, Mei and Liu, Chenxin and Du, Bin},
title = {Core–Shell Nanoparticles with Sequential Drug Release Depleting Cholesterol for Reverse Tumor Multidrug Resistance},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.4c17858}
}
EUVIMED